To demonstrate feasibility of imaging Cu-25%-CANF-Comb uptake in the atherosclerosis of
the carotid artery of patients for whom carotid artery endarterectomy surgery is planned in
comparison to the carotid artery for which intervention is not planned.
This study is a single center, open-label baseline controlled imaging study designed to
demonstrate feasibility of PET imaging of radiopharmaceutical nanoparticle
Cu-25%CANF-Comb uptake by PET-MR. Patients will undergo Cu-25%CANF-Comb PET-MR
imaging of both carotid arteries. Both carotid arteries will be imaged at the same time. We
hope to demonstrate differences in PET SUV (Standardized Uptake Value) in the significantly
atherosclerotic artery in patients who will be going to carotid endarterectomy surgery in
comparison to the PET SUV in the artery that is not significantly diseased (ie; the artery
that will not undergo surgery) . We also will determine whether PET SUV of the
Cu-25%CANF-Comb by the plaque correlates to the American Heart Association
classifications of atherosclerosis and tissue presence of NPR-C in the ex vivo carotid
endarterectomy specimen post surgery as measured by RT-PCR.
- Patients with carotid atherosclerosis
- Patients must be scheduled for carotid intervention (endarterectomy surgery)
- Signed informed consent.
- Unstable clinical conditions
- Pregnancy and lactation
- Inability to lie still for up to 60 min with arms down at sides for PET-MR imaging
- Unwilling to comply with study procedures and unavailable for the duration of the
- Pacemakers, brain aneurysm clip, shrapnel and other typical contraindications for MRI
- Inability to provide written informed consent.